Reported Consolidated quarterly numbers for Divis Laboratories are: Net Sales at Rs 2,604.00 crore in December 2025 up 12.29% ...

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the ...

Welcome to the Divis Labs Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

This article first appeared on GuruFocus. Divi's Laboratories Ltd (NSE:DIVISLAB) is set to release its Q3 2026 earnings on Feb 11, 2026. The consensus estimate for Q3 2026 revenue is $25.96 billion, ...

Management said operational metrics improved during the quarter despite near-term revenue softness and indicated that growth ...

Welcome to the Divis Labs Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most ...

Jefferies appeared the most bullish on the counter, hiking the target price, while Morgan Stanley reduced the target price, citing a subdued environment in the Generics' business.

The stock of Divi’s Laboratories (₹6,473.50) has been moving in a long range between ₹5,250 and ₹7,000 in the last one year. Immediate support levels are at ₹6,359 and ₹6,200. Nearest resistances are ...

Murali Krishna Divi Chairman and managing director, Divis Laboratories Age: 63 Rank in the Rich List: 45 Net Worth: $2.03 billion The Big Challenge Faced in the Last Year: Managing growth in an ...

HYDERABAD, Aug 14 (Reuters) - Indian pharmaceutical company Divi's Laboratories (DIVI.NS), opens new tab reported a 49.2% fall in quarterly profit, missing analysts' estimates, as the generic drug ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey BENGALURU (Reuters) - Shares of ...

Reported Standalone quarterly numbers for Divis Laboratories are: Net Sales at Rs 2,578.00 crore in December 2025 up 12.23% ...